Hims & Hers Health, Inc. (HIMS) Stock: Telehealth Provider Soars Following Rating Upgrade and Strong Earnings

TLDR:

HIMS stock jumped 15.92% to $64 on Tuesday after Truist Securities upgraded its price target Q1 earnings showed 111% revenue growth to $586 million and 346% net income growth to $49.5 million Company’s partnership with Novo Nordisk to market Wegovy drugs on its telehealth platform boosted investor confidence Monthly revenue per subscriber increased by 53% as more users adopt personalized solutions HIMS provided updated 2025 guidance with expected full-year revenues between $2.3-2.4 billion

---

Hims & Hers Health continues its impressive market performance, extending its winning streak for a third consecutive day on Tuesday. The telehealth provider’s stock surged 15.92% to close at $64 per share after receiving a price target upgrade from Truist Securities.

Hims & Hers Health, Inc. (HIMS)

The investment firm raised its target for HIMS from $33 to $45 while maintaining a “hold” rating on the stock. This adjustment came following the company’s first-quarter earnings report, which Truist described as a “mixed bag.”

The Q1 results revealed extraordinary growth across key financial metrics. Revenue soared 111% year-over-year to $586 million, compared to $278.2 million in the same period last year. This represents the highest growth rate since the company went public.

Net income showed even more dramatic improvement, expanding 346% to $49.5 million from $11.1 million in the prior year. The company’s free cash flow surged by 321%, demonstrating the strength of its business model.

Growing Through Personalization

A key driver behind this growth has been the company’s success in increasing the value of each customer relationship. Monthly revenue per subscriber jumped 53%, indicating that users are adopting more personalized, higher-margin offerings.

The shift toward personalization is clear in the numbers. Of the company’s 2.4 million subscribers, over 1.4 million (58.3%) are now using personalized solutions. This represents a major increase from just 21.9% two years ago.

In the dermatology segment, the adoption rate is even higher, with 80% of users opting for personalized plans. This trend toward customization is expected to continue as the company expands its diagnostic capabilities.

The recent Trybe acquisition, which enables blood testing and further personalization, is likely to accelerate this growth in the coming quarters. These personalized subscriptions tend to be stickier and more valuable over time.

Strategic Partnerships and Weight Management Success

Another factor fueling investor excitement is HIMS’ recent partnership with Novo Nordisk. The collaboration will see the companies jointly market the blockbuster Wegovy weight loss drugs on HIMS’ telehealth platform.

The weight management segment is already showing strong results. The company’s oral weight loss product posted 300% year-over-year growth, proving that HIMS is capturing market share in this rapidly expanding sector.

With nearly 100 million Americans struggling with obesity, the total addressable market is massive. HIMS’ lower-cost oral solution, priced at about two-thirds the cost of branded GLP-1s, positions it competitively in this space.

Updated Financial Guidance

Based on its strong performance, HIMS has updated its guidance for 2025. The company now expects full-year revenues to settle between $2.3 billion and $2.4 billion.

For the second quarter, HIMS projects revenue of $530 million to $550 million. While management cautioned that monthly revenue per subscriber might dip slightly in Q2, the long-term trajectory remains positive.

The company’s long-term outlook is even more ambitious. HIMS is targeting $6.5 billion in revenue and $1.3 billion in adjusted EBITDA by 2030, representing compound annual growth rates of 21% and 28%, respectively.

Current profitability metrics are also impressive. Operating cash flow came in at $109 million with $50 million in free cash flow. Gross margin stood at 73%, which was slightly below estimates due to a mix shift toward lower-margin GLP-1 products.

EBITDA margin climbed to 16% in Q1, though full-year 2025 guidance suggests a pullback to 13%. The company appears to be efficiently funding its growth internally, with improving unit economics.

HIMS is also beginning its international expansion. The company has just launched in the UK, where the state of the National Health Service and high private care costs create favorable conditions for HIMS’ direct-to-consumer model.

With limited local competition and high demand for affordable, accessible care in international markets, HIMS could replicate its U.S. success globally in the coming years.

Investors appear to be recognizing this potential, as reflected in the stock’s recent performance. At Tuesday’s closing price of $64, HIMS stock has become one of the market’s top performers.

The post Hims & Hers Health, Inc. (HIMS) Stock: Telehealth Provider Soars Following Rating Upgrade and Strong Earnings appeared first on CoinCentral.